EU New Variations Guidelines to Streamline Lifecycle Management of Medicines
- Home
- regulatory updates
- EU New Variations Guidelines to Streamline Lifecycle Management of Medicines
EU New Variations Guidelines to Streamline Lifecycle Management of Medicines
Regulatory Affairs Pharma & Biotech
Tuesday, 30 September 2025
Miguel Gutierrez, Consultant RA Pharma and Peter Fry, Business Unit Manager, RA Pharma & Country Manager, UK
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
The European Commission has published the final version of the new Variations Guidelines for human medicines, which will take effect on 15 January 2026 and are designed to support the new Variations Regulation that entered into force in January 2025.
EU New Variations Guidelines to Streamline Lifecycle Management of Medicines
2:25
The aim of the newvariations framework is to streamline post-approval change handling, particularly the assessment and processing of variations.
Key takeaways
Scope & purpose
Harmonized rules and procedures for managing Type IA/IB/II variations, with an emphasis on efficiency and fit-for-innovation lifecycle management (including medicines used with medical devices).
When it applies
For variation applications submitted to EMA from 15 January 2026.
What’s coming next
EMA will update the post-authorisation procedural guidance by end-December 2025, to include additional practical details on changes resulting from the new variation guidelines. This will include practical information on regulatory tools detailed in ICH Q12 such as post-authorisation change management protocols ( PACMP) and the product lifecycle management document ( PLCM).
Who is affected?
Marketing Authorization Holders (MAHs) for medicinal products authorised in the EU via the Centralised Procedure or National Procedures such as the Decentralised and Mutual-Recognition Procedure should be aware of the updated legislation and guidance.
How QbD Group can support
Conduct a focused review of SOPs
pending change controls and planned submissions to ensure alignment with the requirements detailed in the new framework.
Author Variation submissions
We can offer comprehensive post-approval support, starting from analysis of the initial change control, to preparation and review of documentation, eCTD publishing, submission and approval.
Provide training
training on the application of the new framework, covering key changes to grouping, worksharing, classification of changes, updated document requirements and consequential impacts to regulatory strategy. Other complimentary changes can be covered, such as implementation of the Product Lifecycle Management (PLM) Portal.
If you are looking for comprehensive Regulatory Intelligence support that monitors changes to key legislation and guidance, please don’t hesitate to get in touch with one of our experts today!
Discover more expert content
Previous
Regulatory Affairs
27 Jun 2024
Updated Guidance on MDR Surveillance: MDCG 2022-4, Revision 2
Guidance on appropriate surveillance regarding the transitional provisions under Article 120 of the...
Regulatory Affairs
27 Jun 2024
MDCG 2024-10: Clinical Evaluation Guidelines for Orphan Medical Devices
MDCG 2024-10 Clinical evaluation of orphan medical devicesThis document provides guidance to...
Regulatory Affairs
5 Nov 2024
New Q&A on the obligation to inform in case of interruption or discontinuation of supply
On October 30th, 2024, the Medical Device Coordination Group (MDCG) released a Q&A on the...
Regulatory Affairs
14 Oct 2024
MDCG 2024-11 released
Regulatory Affairs
11 Sep 2025
EU Pharmacovigilance: Implementing Regulation (EU) 2025/1466
Key updates {% module_block module "widget_d5c7897b-e64e-4654-8217-f0d1e3a45cd1" %}{%...
Regulatory Affairs
27 Jun 2024
Updated Guidance on MDR Surveillance: MDCG 2022-4, Revision 2
Guidance on appropriate surveillance regarding the transitional provisions under Article 120 of the...
Regulatory Affairs
27 Jun 2024
MDCG 2024-10: Clinical Evaluation Guidelines for Orphan Medical Devices
MDCG 2024-10 Clinical evaluation of orphan medical devicesThis document provides guidance to...
Regulatory Affairs
5 Nov 2024
New Q&A on the obligation to inform in case of interruption or discontinuation of supply
On October 30th, 2024, the Medical Device Coordination Group (MDCG) released a Q&A on the...
Regulatory Affairs
14 Oct 2024
MDCG 2024-11 released
Regulatory Affairs
11 Sep 2025
EU Pharmacovigilance: Implementing Regulation (EU) 2025/1466
Key updates {% module_block module "widget_d5c7897b-e64e-4654-8217-f0d1e3a45cd1" %}{%...
Regulatory Affairs
27 Jun 2024
Updated Guidance on MDR Surveillance: MDCG 2022-4, Revision 2
Guidance on appropriate surveillance regarding the transitional provisions under Article 120 of the...
Regulatory Affairs
27 Jun 2024
MDCG 2024-10: Clinical Evaluation Guidelines for Orphan Medical Devices
MDCG 2024-10 Clinical evaluation of orphan medical devicesThis document provides guidance to...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe